People undergoing metabolic and bariatric surgery (MBS) are less likely to develop psychiatric disorders than those treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs).

GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 ...

"These drugs have the potential to change societies, not just individuals." — Michael Le Page, New Scientist, March 29, 2025 ...

As rates of MASLD, which is linked to obesity and diabetes, rise, new therapies have emerged, but better diagnostic and ...

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

In 2025, each issue of Population Health, Equity & Outcomes will feature a profile of a health system leader transforming ...

Infection, delayed kidney function, kidney loss and death are all risks associated with kidney transplant surgery in obese ...

Expect social and relationships to change after weight loss. The more weight you lose and the more you change your lifestyle to achieve healthy weight loss, the more likely relationships are to change ...

A new study reports that people taking GLP-1 drugs in daily life don’t lose as much weight as those in clinical trials who ...